ClinicalTrials.gg
CompletedNCT04246749Updated Jan 29, 2020

Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers

A Phase 1 interventional study of [14C]-CRN00808 and CRN00808 in Healthy Volunteers, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 1 site in Netherlands. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-29.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Sep 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

A phase 1 healthy volunteer study to assess the mass balance, elimination, and metabolic profile of CRN00808. The study will be conducted in 2 parts: Part A, to characterize the absorption, distribution, metabolism, excretion, and mass balance of orally administered radio-labeled CRN00808; Part B, to determine the absolute bioavailability of CRN00808 administered using CRN00808 and radio-labeled CRN00808 as intravenous and oral forms.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects 19 to 55 years of age
  2. 18 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Any uncontrolled or active major systemic disease including, but not limited to: acromegaly (with or without pituitary surgery or radiation therapy), cardiac, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with potential
  2. History or presence of within the past 5 years. Subjects who have been successfully treated (for 3 months or longer) with no recurrence of basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.
  3. Use of any drug within the past 60 days or 5 half-lives, whichever is longer
  4. Have a medically significant abnormality observed during screening or the admission physical examination or in any other baseline measurements
  5. Use of any prior medication without approval of the investigator within 14 days prior to admission
  6. Tested positive at screening for , surface antigen (HBsAg) or antibody (HCV-Ab) or has a history of a positive result
  7. History of alcohol or substance abuse in the past 6 months
  8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this Phase 1 study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Part A: [14C]-CRN00808 Oral Solution

    Single oral dose of CRN00808 containing \[14C\]-CRN00808

    Drug: [14C]-CRN00808

  • Experimental
    Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer

    Single oral dose of CRN00808 followed by \[14C\]-CRN00808 IV microtracer injection

    Drug: [14C]-CRN00808 · Drug: CRN00808

Interventions

06

What researchers measure

Primary outcomes

  1. Mass balance of CRN00808

    Total radioactivity in urine and feces following a single oral dose \[14C\]-CRN00808 (expressed as a percentage of the total radioactive dose administered)

    Time frame: Up to 21 days (until >90% of dose is recovered)

  2. Absolute bioavailability of CRN00808

    Absolute bioavailability is calculated from the areas under the curve of intravenous and oral administration

    Time frame: 5 days

Secondary outcomes

  1. Pharmacokinetics (AUC)

    Assessment of the plasma area under the curve of CRN00808 and \[14C\]-CRN00808

    Time frame: Part A: Day 1 to day 21 (depending on recovery of dose). Part B: Day 1 through to Day 7

  2. Pharmacokinetics (t1/2)

    Assessment of the total elimination half-life of CRN00808 and \[14C\]-CRN00808

    Time frame: Part A: Day 1 to day 21 (depending on recovery of dose). Part B: Day 1 through to Day 7

  3. Pharmacokinetics (Tmax)

    Assessment of Time to attain maximum observed plasma concentration of CRN00808 and \[14C\]-CRN00808

    Time frame: Part A: Day 1 to day 21 (depending on recovery of dose). Part B: Day 1 through to Day 7

  4. Pharmacokinetics (CL)

    Assessment of the clearance of CRN00808 (Part B only)

    Time frame: Day 1 through to Day 7

  5. Pharmacokinetics (CL/F)

    Assessment of Apparent oral clearance of CRN00808

    Time frame: Part A: Day 1 to day 21 (depending on recovery of dose). Part B: Day 1 through to Day 7

  6. Pharmacokinetics (Vz)

    Assessment of Volume of distribution at terminal phase (Part B only)

    Time frame: Day 1 through to Day 7

  7. Pharmacokinetics (Vz/F)

    Assessment of Apparent volume of distribution at terminal phase

    Time frame: Part A: Day 1 to day 21 (depending on recovery of dose). Part B: Day 1 through to Day 7

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Oct 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 29, 2020
StartActual
Sep 17, 2019
Primary completionActual
Oct 25, 2019
CompletionActual
Oct 25, 2019
Last update
Jan 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04246749
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Sep 17, 2019
Primary completion
Oct 25, 2019
Completion
Oct 25, 2019
Last update
Jan 29, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paltusotine

Start the discussion